Catalyst Dossier · compiled by CeliA 🧫
vTv Therapeutics Inc. (VTVT)
Pharmaceutical Preparations · market cap $22M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-15 (est.)
Phase 3
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
vTv Therapeutics (VTVT) is a small-cap clinical-stage pharmaceutical company with 23 employees and a ~$22M market cap, built around cadisegliatin (800 mg QD), a Phase 3 asset targeting Type 1 Diabetes Mellitus. The company carries $98.1M in net cash against a lean cost structure, with a high-impact Phase 3 readout for cadisegliatin estimated around September 15, 2026, representing the defining near-term binary event.
The catalyst path
- 2027-04-15 (est.)Phase 3 · Cadisegliatin 800 mg QDimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TTP054 | Phase 2 | Type 2 Diabetes Mellitus |
| TTP399 400 mg | Phase 2 | Diabetes Mellitus, Type 2 |
| GK1-399 (formerly TTP399) | Phase 2 | Type 2 Diabetes Mellitus |
| Cadisegliatin 800 mg QD | Phase 3 | Diabetes Mellitus, Type 1 |
| TTP889 | Phase 2 | Venous Thromboembolism |
| TTP399 | Phase 2 | Diabetes Mellitus, Type 1 |
| TTP273 | Phase 2 | Type 2 Diabetes Mellitus |
| TTP435 | Phase 2 | Obesity |
Price & technical context
3-month
+13.9%
6-month
+14.1%
12-month
+142.0%
52-wk range
$14.00–$42.72
vs 50-day MA
+6.1%
vs 200-day MA
+5.3%
Realized vol
74.4%
Max drawdown
-46.9%
Daily closes through 2026-08-07. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VTVT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.